Original language | English |
---|---|
Pages (from-to) | 1970-1971 |
Number of pages | 2 |
Journal | HemaSphere |
DOIs | |
Publication status | Published - 23 Jun 2022 |
PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL
A. Sharp, Anja Williams, Sarah Blagden, R. Plummer, D. Hochhauser, Matthew Krebs, Simon Pacey, J. Evans, Sarah Whelan, S. Nandakumar, S. Rogers, K. Jameson, F. Basile, J. Bono, H.-T Arkenau
Research output: Contribution to journal › Meeting Abstract › peer-review